ATE241384T1 - Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden - Google Patents

Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden

Info

Publication number
ATE241384T1
ATE241384T1 AT96908900T AT96908900T ATE241384T1 AT E241384 T1 ATE241384 T1 AT E241384T1 AT 96908900 T AT96908900 T AT 96908900T AT 96908900 T AT96908900 T AT 96908900T AT E241384 T1 ATE241384 T1 AT E241384T1
Authority
AT
Austria
Prior art keywords
organic
preparation
soluble carbohydrates
moiety
immunogenic constructs
Prior art date
Application number
AT96908900T
Other languages
English (en)
Inventor
Andrew Lees
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/408,717 external-priority patent/US5651971A/en
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Application granted granted Critical
Publication of ATE241384T1 publication Critical patent/ATE241384T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96908900T 1995-03-22 1996-03-22 Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden ATE241384T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/408,717 US5651971A (en) 1993-09-22 1995-03-22 Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US48266195A 1995-06-07 1995-06-07
PCT/US1996/004013 WO1996029094A1 (en) 1995-03-22 1996-03-22 Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents

Publications (1)

Publication Number Publication Date
ATE241384T1 true ATE241384T1 (de) 2003-06-15

Family

ID=27020359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908900T ATE241384T1 (de) 1995-03-22 1996-03-22 Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden

Country Status (9)

Country Link
EP (1) EP0814833B1 (de)
JP (2) JPH11502820A (de)
AT (1) ATE241384T1 (de)
AU (1) AU712981B2 (de)
CA (1) CA2215933C (de)
DE (1) DE69628418T2 (de)
ES (1) ES2200059T3 (de)
NZ (1) NZ304715A (de)
WO (1) WO1996029094A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6087328A (en) * 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US6284250B1 (en) 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
WO1999064603A2 (en) * 1998-06-12 1999-12-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
AU2064201A (en) * 1999-12-06 2001-06-12 Eukarion, Inc. Carbohydrate-aminated glycoproteins
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2844154C (en) * 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014102265A1 (en) 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
CN103113836B (zh) * 2013-03-09 2015-08-12 谭志刚 一种白乳胶添加剂及其制备方法
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3244917B1 (de) 2015-01-15 2023-04-19 Pfizer Inc. Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
DK3313436T3 (da) 2015-06-23 2021-03-08 Biological E Ltd Multivalent pneumokok-konjugatvaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
PH12019500672B1 (en) 2016-09-30 2024-02-23 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR102701633B1 (ko) 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
US12018134B2 (en) 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
TWI852943B (zh) 2018-09-12 2024-08-21 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2019341723C1 (en) 2018-09-23 2026-01-22 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
WO2020075201A1 (en) 2018-10-12 2020-04-16 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
EP3897705A2 (de) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Zusammensetzungen mit polysaccharidproteinkonjugaten von streptococcus pneumoniae und verfahren zu deren verwendung
EP3923982A1 (de) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3757217A1 (de) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur proteinaufreinigung
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
CA3185429A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
BR112022023234A2 (pt) 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4232593A1 (de) 2020-10-22 2023-08-30 Pfizer Inc. Verfahren zur reinigung von bakteriellen polysacchariden
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
EP4452308A1 (de) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Impfstoff
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20260051063A (ko) 2023-08-09 2026-04-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) * 1967-12-20 1972-03-06 Pharmacia Ab
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
DE3541186A1 (de) * 1985-11-21 1987-05-27 Boehringer Mannheim Gmbh Wasserloesliche, stabilisierte peroxidasederivate, verfahren zu ihrer herstellung und verwendung zur bestimmung von wasserstoffperoxid
ATE111746T1 (de) * 1989-11-15 1994-10-15 Sandoz Ag Polymyxinkonjugate.
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.

Also Published As

Publication number Publication date
DE69628418T2 (de) 2004-04-01
EP0814833A1 (de) 1998-01-07
CA2215933A1 (en) 1996-09-26
JPH11502820A (ja) 1999-03-09
JP2008101022A (ja) 2008-05-01
NZ304715A (en) 1999-07-29
DE69628418D1 (de) 2003-07-03
AU5259196A (en) 1996-10-08
EP0814833B1 (de) 2003-05-28
AU712981B2 (en) 1999-11-18
ES2200059T3 (es) 2004-03-01
CA2215933C (en) 2009-10-13
WO1996029094A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
DE69628418D1 (de) Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
DE122009000058I1 (de) Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
WO1995008348B1 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
ATE267255T1 (de) Ob proteinderivate mit verlängerter halbwertzeit
DE69325096D1 (de) Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
DE69826851T2 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
ATE232210T1 (de) Verfahren zur herstellung von erythromicin a-oxim
DK0870014T3 (da) Katalytiske antistoffer mod aldolase
HK1044288A1 (zh) 制造5'核酸蛋白质结合的方法
WO1995029927A3 (en) Process for preparation of glycosides of tumor-associated carbohydrate antigens
DE59808194D1 (de) Verfahren zur herstellung von triazolinthion-derivaten
ATE285790T1 (de) Herstellungsverfahren von festphasekonjugateimpfstoffen
DE3773077D1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
DE69535764D1 (de) 9,9'- bis-acridin-derivate und signallösungen
DE122009000055I1 (de) Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
AU5045493A (en) Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein
NO920163L (no) Hydrolysert vegetabilsk protein og fremstilling av et slikt
ATE48612T1 (de) Konjugate von adenin-9-beta-arabinofuranosid-5'monophosphat mit menschlichem lactosaminiertem albumin, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE59803194D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
WO1997020855A3 (en) Solid phase organic synthesis
ATE96154T1 (de) Biotechnisches verfahren zur gewinnung von reiner, protein-freier staerke aus erbsen.
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
EP0569531A4 (de) Stabilisierte antikörperfragmente.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties